期刊文献+

急性冠脉综合征患者血栓调节蛋白水平及临床意义 被引量:3

The clinical significance and level of thrombombdulin in patients with acute coronary syndrome
下载PDF
导出
摘要 目的:观察急性冠脉综合征(ACS)患者血栓调节蛋白(TM)水平变化,并结合冠状动脉造影(CAG)结果探讨其临床意义。方法:测定经CAG证实为CHD患者(CHD组,n=56)的TM浓度,且与CAG结果正常组(对照组,n=30)的血浆浓度比较,分析两组间TM浓度的关系及CHD(AP、UAP、AMI)组中TM浓度与冠脉病变程度的关系。结果:对照组、AP组、UAP组、AMI组TM浓度依次增高,分别为(20.24±7.09)、(50.14±8.92)、(69.18±8.12)、(90.19±10.32)pg/L;CAG为单支、双支、三支病变者,其浓度亦依次增高,分别为(50.14±8.92)、(71.34±8.18)、(91.16±9.14)pg/L。结论:CHD患者TM浓度明显升高,且随病变程度加重及冠脉病变范围的扩大而升高。 Objective: To observe the change of thrombombdulin (TM) level and combine with coronary angiography (CAG) results of patients with acute coronary syndrome (ACS) to explore its clinical significance. Methods: The plasma TM concentrations of 56 patients with CHD confirmed by CAG were tested, and were compared with 30 cases of normal control group, the relationship between the TM concentrations of the two groups and different numbers of diseased coronary vessels in CHD (AP, UAP and AMI) group were analyzed. Results: The plasma TM concentrations were (20.24±7.09), (50.14±8.92), (69.18±8.12) and (90.19±10.32) pg/L respectively. The plasma TM concentrations were (50.14±8.92), (71.34±8.18) and (91.16±9.14) pg/L respectively for the one-vessel-disease group, the two-vessel-disease group, and the three-vessel- disease group. Conclusion: The plasma TM concentrations are significantly elevated with the severity of the disease and CAG in patients with CAD.
出处 《中国医药导报》 CAS 2009年第28期25-26,共2页 China Medical Herald
关键词 冠心病 血栓调节蛋白 冠状动脉造影 冠脉病变支数 Coronary heart disease Thrombombdulin Coronary arteriography Number of diseased coronary vessels
  • 相关文献

参考文献6

二级参考文献23

  • 1章宏祥,段宝祥.血浆血栓调节蛋白的含量与冠心病[J].医学综述,2005,11(3):218-220. 被引量:1
  • 2于丽天,朱俊,Rebecca Mister,章晏,李建冬,王多劳,刘力生,Marcus Flather.我国部分医院ST段抬高急性冠状动脉综合征再灌注治疗登记研究[J].中华心血管病杂志,2006,34(7):593-597. 被引量:30
  • 3Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coil Cardiol, 2004,44: 671-719.
  • 4Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 2006, 113 : 2363-2372.
  • 5Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the mediterranean basin. The survey of acute coronary syndromes. Eur Heart J, 2002, 23:1190- 1201.
  • 6Carruthers KF, Dabbous OH, Flather MD, et al. Contemporary management of acute coronary syndromes : does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart, 2005, 91: 290-298.
  • 7Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA, 2006, 295: 1912-1920.
  • 8饶克勤.中国卫生统计年鉴2005.北京:协和医科大学出版社,2006:3-15.
  • 9Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 2006, 113: 203-212.
  • 10Blann AD,Seigneur M,Steiner M,et al.Circulating endothelial cell markers in peripheral vascular disease:relationship to the location and entent of atherosclerotic disease.Eur J Clin Invest,1997,27:916-921

共引文献56

同被引文献44

  • 1沈培辰,张代富,王娟,马兰.急性心肌梗死患者血浆TAT变化的价值[J].实用全科医学,2005,3(6):477-478. 被引量:5
  • 2CARNEMOLLA R, GREINEDER CF, CHACKO AM, et al. Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo[ J]. J Pharmacol Exp Ther,2013,347 (2) :339-345.
  • 3CHAO TH, TSAI WC, CHEN JY, et al. Soluble thrombomodulin is a paracrine anti-apoptotic factor for vascular endothelial protection[ J]. int J Cardiol,2014,15 ; 172 (2) :340-34.
  • 4LI YH,HSIEH CY,WANG DL,et al. Remodeling of carotid arteries isassociated with increased expression of thrombomodulin in a mouse transverse aortic constriction model [ J ]. Thromb Haemost, 2008,97 (4) :658-664.
  • 5BLANN AD,TABEMER DA. Areliable maiker of endothelial cell dys- function : does it exist[ J ]. Br J Haematol, 1995,90 (2) :224-229.
  • 6SON BK, AKISHITA M, IIJIMA K, et al. Thrombomodulin, a novel molecule regulating inorganic phosphate-induced vascular smooth muscle cell calcification[ J]. J Mol Cell Cardiol,2013 ,56 :72-80.
  • 7LIN WL, CHANG CF, SHI CS, et al. Recombinant lectin- like domain of thrombomodulin suppresses vascular inflammation by reducing leu- kocyte recruitment via interacting with Lewis Y on endothelial cells [ J]. Arterioscler Thromb Vasc Biol,2013,33 (10) :2366-2373.
  • 8WEI HJ, LI YH, SHI GY, et al. Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activa- tion[ J]. Cardiovasc Res,2011,92(2) :317-327.
  • 9OHLINAK, LARSSONK, ItANSSONM. Soluble thrombomodulin activ- ity and soluble thrombomodulin antigeninplasma [ J ]. ThrombHaem- ost,2005,3 (5) :976-982.
  • 10LI YH,CHENCH,YEHPS,et al. Functional mutation in the promoter region of Thrombomodulin gene in relation to carotid atherosclerosis [ J]. Atherosclerosis ,2001,154( 1 ) :713-719.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部